Dimensional Fund Advisors’s TG Therapeutics TGTX Stock Holding History

Dimensional Fund Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.5M	Buy	1,210,578 +125,723	+12%	+$5.15M	0.01%	1436
2026 Q1	$36M	Buy	1,084,855 +612,068	+129%	+$18.2M	0.01%	1684
2025 Q4	$14.1M	Buy	472,787 +446,884	+1,725%	+$14.6M	﹤0.01%	2152
2025 Q3	$936K	Buy	+25,903	New	+$853K	﹤0.01%	2900
2021 Q3	–	Sell	-31,450	Closed	-$1.22M	–	3533
2021 Q2	$1.22M	Sell	31,450 -53,803	-63%	-$2.11M	﹤0.01%	2993
2021 Q1	$4.11M	Buy	85,253 +79,765	+1,453%	+$3.83M	﹤0.01%	2640
2020 Q4	$285K	Buy	+5,488	New	+$185K	﹤0.01%	3181
2019 Q1	–	Sell	-71,312	Closed	-$292K	–	3461
2018 Q4	$292K	Buy	71,312 +6,812	+11%	+$33.9K	﹤0.01%	3229
2018 Q3	$361K	Buy	+64,500	New	+$737K	﹤0.01%	3223
2015 Q2	–	Sell	-13,089	Closed	-$203K	–	3372
2015 Q1	$203K	Buy	+13,089	New	+$198K	﹤0.01%	3226

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Dimensional Fund Advisors's TGTX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its TG Therapeutics (TGTX) stake by 12% in Q2 2026, buying an estimated $5.15M and bringing the position to 1,210,578 shares worth $66.5M. The position accounts for 0.01% of the portfolio, ranked #1436.

Dimensional Fund Advisors first reported a position in TGTX in Q1 2015 and has held it in 10 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Dimensional Fund Advisors held 1,210,578 shares of TG Therapeutics worth $66.5M as of Q2 2026.
Dimensional Fund Advisors bought 125,723 TG Therapeutics shares in Q2 2026, an estimated $5.15M.
TG Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1436 holding.
Dimensional Fund Advisors first reported a position in TG Therapeutics in Q1 2015 and has held it in 10 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.